{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-034580","form_type":"8-K","ticker":"ACET","cik":"0001720580","company_name":"Adicet Bio, Inc.","filed_at":"2025-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.581654+00:00","generated_at":"2026-05-25T06:48:30.320485+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Adicet Bio Q4 net loss $0.32/share, cash $176.3M; expects ADI-001 LN data in 1H25","bullets":["Q4 2024 net loss $28.7M ($0.32/share) vs. $29.5M ($0.69/share) in Q4 2023; full year net loss $117.1M.","Cash, cash equivalents and short-term investments $176.3M as of Dec 31, 2024; expected to fund ops into 2H26.","Phase 1 trial of ADI-001 in autoimmune diseases: LN patient preliminary data expected 1H25; enrollment for SLE, SSc, IIM, SPS to start 2Q25.","ADI-270 Phase 1 in ccRCC: preliminary data expected 1H25; first patient dosed Dec 2024.","Received FDA Fast Track Designation for ADI-001 in refractory SLE with extrarenal involvement and SSc (Feb 2025)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-034580","json":"https://secwatch.observer/filing/0000950170-25-034580.json","markdown":"https://secwatch.observer/filing/0000950170-25-034580.md","text":"https://secwatch.observer/filing/0000950170-25-034580.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720580/000095017025034580/0000950170-25-034580-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720580/000095017025034580/acet-20250306.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T06:48:30.320485+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}